Chf10067
Phase 2
Chiesi Farmaceutici S.p.A.Chf10067 is one of 41 therapeutic programs targeting Idiopathic Pulmonary Fibrosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
46 competitors in Idiopathic Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Esbriet
LLegacy Health System
Approved
Medrol
PfizerApproved
Viagra
VViatris Specialty LLC
Approved
Remodulin
United TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Qvar
SSchering-Plough
Approved
Rayos
RRoxane Laboratories
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Chf10067. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company